EXEL
Exelixis, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -4.8% ·
share flow -1.3% ·
net new positions -10.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 343.80K | $18.50M | n/a | n/a |
| Q2 2026 | 137 | -1 | 179.98M | $9.79B | +5 | −8 |
| Q1 2026 | 143 | -1 | 180.18M | $7.73B | +4 | −6 |
| Q4 2025 | 143 | +1 | 192.52M | $8.44B | +2 | n/a |
| Q3 2025 | 20 | -1 | 116.93M | $4.83B | n/a | −2 |
| Q2 2025 | 19 | +2 | 115.09M | $5.07B | +2 | n/a |
| Q1 2025 | 14 | -1 | 52.64M | $1.94B | +1 | −2 |
| Q4 2024 | 15 | +1 | 49.00M | $1.63B | +1 | n/a |
| Q3 2024 | 13 | 0 | 34.27M | $889.30M | n/a | n/a |
| Q2 2024 | 13 | n/a | 31.74M | $712.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 29.37M | -2.3% | $1.21B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (passive) | 26.06M | -5.1% | $1.08B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 15.46M | -2.3% | $638.47M | 0.8% | ▼ Trim | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 11.11M | -2.4% | $459.04M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 9.18M | +20.7% | $379.19M | 0.2% | ▲ Add | 6 | SEC ↗ ×5 |
| 6 | Geode Capital Management ✦ (passive) | 7.67M | +3.0% | $316.85M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Arrowstreet Capital ✦ | 5.27M | +0.1% | $217.57M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 3.21M | n/a | $132.60M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 9 | JPMorgan Chase ✦ | 1.88M | n/a | $77.80M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 10 | Fidelity (FMR) ✦ | 1.79M | -33.9% | $73.74M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 11 | T. Rowe Price ✦ | 1.13M | -22.0% | $46.74M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 1.08M | +84.5% | $44.45M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 1.00M | n/a | $41.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Bridgewater Associates ✦ | 842.97K | +3940.1% | $34.81M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 834.02K | -1.4% | $34.44M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 640.28K | +409.6% | $26.44M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | D. E. Shaw & Co. ✦ | 225.43K | -62.6% | $9.31M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 18 | Wellington Management ✦ | 88.17K | -10.9% | $3.64M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 19 | Fisher Asset Management ✦ | 46.81K | +4.4% | $1.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 39.31K | -93.9% | $1.62M | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $122.10M | was 0.0% |
| Marshall Wace | $6.95M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 692 holders, 256.72M shares, $10.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 9.81K sh · $526,512
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
5.6% of class · View original SEC filing ↗